FDA approval used to be the finish line. Now, it’s barely the halfway point. Medicare price negotiation is reshaping which molecules and indications make commercial sense, the EU’s Joint Clinical Assessment framework is already exposing evidence gaps that regulatory-only strategies never anticipated, and FDA advisory committees are delivering contentious, unpredictable outcomes where strong science isn’t enough to win the room. The companies still treating regulatory, evidence generation, and payer strategy as sequential handoffs are bleeding value at every transition, often without realizing it until access stalls.
Why is the old playbook obsolete? What does it take to build a strategy where approval and access are planned together, years before submission?
Download the full read to see why integrated expertise isn’t a nice-to-have anymore. It’s the only structure built for the environment biopharma now operates in.
Download the Full Executive Perspective
"*" indicates required fields
